Renalytix (LON:RENX) Trading Up 2.6% – Here’s What Happened

Renalytix Plc (LON:RENX)’s share price traded up 2.6% on Tuesday . The company traded as high as GBX 2 and last traded at GBX 2. 684,095 shares changed hands during trading, a decline of 25% from the average session volume of 914,129 shares. The stock had previously closed at GBX 1.95.

Renalytix Stock Down 6.7%

The firm has a 50-day simple moving average of GBX 2.75 and a 200 day simple moving average of GBX 5.36. The company has a market capitalization of £7.95 million, a PE ratio of -0.46 and a beta of 1.97. The company has a debt-to-equity ratio of -118.57, a current ratio of 1.21 and a quick ratio of 2.42.

Renalytix Company Profile

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).